Trial Profile
A clinical and pharmacologic study of the combination of erlotinib and bexarotene in resectable clinical stage I-II non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Bexarotene (Primary) ; Erlotinib (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Pharmacodynamics
- 04 Feb 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
- 08 Jan 2013 Planned end date changed from 1 Dec 2012 to 1 May 2013 as reported by ClinicalTrials.gov.
- 19 Oct 2011 Planned end date changed from 1 Dec 2010 to 1 Dec 2012 as reported by ClinicalTrials.gov.